Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers
Status:
Unknown status
Trial end date:
2021-06-07
Target enrollment:
Participant gender:
Summary
Current curative treatment of digestive peritoneal carcinomatosis consists of complete
cytoreduction surgery associated with intraperitoneal chemotherapy. This treatment has
important limits: a high morbimortality and the impossibility of repeating the sessions. The
majority of patients are therefore treated with systemic chemotherapy, which despite its
progress, remains palliative.
Pressurized Intraperitoneal aerosol chemotherapy (PIPAC) has many advantages: under
laparoscopy, low morbidity, good intratumoral penetration of cytotoxics, possibility of
repeating the sessions and low financial cost.
Therefore, the investigator propose a phase 1 study, in colorectal and stomach cancer, with
oxaliplatin doses escalation in Pressurized Intraperitoneal aerosol chemotherapy. It would
allow a better tumor response, with potentially few risks and thus improve survival in
patients with digestive peritoneal carcinoses, increasing access to cytoreductive surgery.